Here’s an opportunity for Optomed to supply a PACS system to Apotti under a 4-year contract. Likely a million-euro deal up for grabs.
Article about Aeye Health in Forbes.
The link leads to a request for tenders related to oral imaging. Was this intentional, or did the wrong link slip in by mistake?
Optomed is the representative for the Sectra PACS system in Finland and the Baltics.
Example case:
Interesting and new to me, I’ll have to look into this more closely. Thanks Sheikki.
For oral healthcare use alone, SECTRA PACS is too expensive a system and cannot compete with manufacturers specializing in dental imaging.
Helsinki-based Planmeca is the clear front-runner to win the tender.
Most likely just as you say.
The requirements state the following:
”
Key requirements for the new PACS system are:
- The system must meet the national requirements for a Class A system
…
””
In the description of the Kanta service, it says:
”
Joint testing is a statutory obligation for Class A information systems.
”
When looking at the list of suppliers who participated in joint testing, Planmeca is not on the list.
Am I off track if I conclude from this that Planmeca is ineligible for the tender due to the lack of joint testing?
There are several twists to this. If read strictly to the letter, the recorded requirement does not mandate that the offered solution must be registered as a Class A system at the time of bid submission. Also, the mention that “The information system to be acquired must have the capabilities for storing images recorded by oral healthcare imaging devices in the Kanta services for their retention period, in the same way as other client documents” suggests that it is not an absolutely strict requirement.
Secondly, regarding the status of the archive for imaging data, the approved tests only concern radiology and ECG data, not oral healthcare imaging data (which has been repeatedly delayed). Thirdly, the offered system can consist of a primary dental imaging system and an accompanying interface solution that is already on that list of system developers for the imaging data archive.
Digital Diagnostics (IDx-DR - currently LumineticsCore) is conducting a clinical trial / comparative study with the giant corporation Labcorp on the use of a handheld camera in screening for diabetic retinopathy. The camera model is not disclosed at this point, but previously Labcorp has conducted screening at least with the Zeiss Visuscout 100 manufactured by Optomed.
….
Official Title: Camera Qualification of an Additional Fundus Camera Paired With An Autonomous AI for Detecting Diabetic Retinopathy
…
Detailed Description:
A multi-center Study to demonstrate substantial equivalence of automated device detecting diabetic retinopathy using a handheld fundus camera with IDx-DR.
….
It would be interesting to know if it is an Optomed camera.
Another ongoing clinical trial with the Optomed Aurora IQ camera is a study by the Turkish-based Eyecheckup.
..
Multicenter Diagnostic Clinical Performance Study For Automated Detection of Diabetic Retinopathy
Perhaps @Juha_Kinnunen could ask in the Q1 report interview if an Optomed camera is being used in that Digital Diagnostics and Labcorp trial?
Thanks for the info, I can certainly ask about that ![]()
Excellent, thanks! ![]()
Below are Juha’s preview comments as Optomed releases its Q1 report on Friday.
Health technology company Optomed will publish its Q1 report on Friday at approximately 9:00 am. We expect revenue to have grown rapidly from a weak comparison period, which was particularly characterized by the collapse of device sales in China. We also forecast that earnings have recovered from the comparison period due to a higher revenue volume, but remained clearly loss-making. The next critical step in Optomed’s investment story is the long-awaited FDA clearance for the Aurora AEYE solution, for which expectations are currently set for the end of Q2’23.
By the way, here is a fairly recent press release regarding the collaboration that has begun between Digital Diagnostics and Labcorp. Undoubtedly, Labcorp also wants to include the handheld camera; that is indicated by the clinical trial I mentioned above.
Glaucoma is rarely discussed in connection with Optomed, but it would be interesting to hear more about that as well.
”
Optomed, together with its partners, is involved in several studies testing, among other things, the performance of AI applications in glaucoma screening. One collaborative project is being carried out with Eija Vesti, Professor of Ophthalmology at Turku University Central Hospital.
”
Greetings,
Feel free to send in more questions for Optomed’s CEO, @Sheikki and others! I’ll then select suitable ones for the Q1 interview on Friday. It’s not worth dwelling too much on the FDA process, though we will of course ask what we can. We’d prefer to explore other themes more.
Tomorrow we’ll be a bit wiser again regarding Optomed’s development ![]()
Here is one question. Optomed received medical device approval for the Aurora camera in Brazil in the spring of 2021, and apparently, a distribution agreement was also signed there. How does the Brazilian market look for Optomed at the moment? The press release stated that Brazil is the most attractive market for Optomed among Latin American countries.
It would be interesting to hear about this as well.
I would like to ask a question: how much revenue comes from Finland compared to other markets?
Follow-up question: has the eye clinics’ new software project already been completed, and have any deals already been agreed?
I’m curious to know how strong the patent protection for Optomed’s Aurora AEYE is once the FDA clearance is granted. I’m mainly interested because the entire case is largely based on this FDA approval. In other words, even if the FDA clearance is obtained, how well are they protected by patents from someone else entering the same market with their own similar handheld camera?